We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Protracted Ketonemia Reported in Hyperglycemic COVID-19 Emergencies

By LabMedica International staff writers
Posted on 03 Aug 2020
Diabetes is a major contributor to disease severity and mortality in patients with COVID-19; with an estimated 3.5-times increase in risk of death during hospital admission for patients with type 1 diabetes, and 2.03-times for those with type 2 diabetes.

Diabetic ketoacidosis (DKA) is a life-threatening problem that affects people with diabetes. More...
It occurs when the body starts breaking down fat at a rate that is to rapid. The liver processes the fat into a fuel called ketones, which causes the blood to become acidic. DKA and hyperosmolar hyperglycemic state (HHS) are hyperglycemic emergencies associated with substantial mortality and high blood sugar levels increase cardiovascular (CV) risk in elderly diabetics.

Endocrinologists at the North Middlesex University Hospital (London, UK) and their colleagues carried out a retrospective analysis of recruited eligible patients from three hospitals in north London, UK, March 1–30, 2020. There were 35 patients with COVID-19, presenting with DKA (31.4%), mixed DKA and HHS (37.1%), HHS (5.7%), or hyperglycemic ketosis (25.7%) that were included and evaluated. The median overall HbA1c was 111 mmol/mol (IFCC; diabetes diagnostic cut-off ≥48 mmol/mol) and/or the presence of ketonemia (beta-hydroxybutyrate >0.6mmol/L). The median age of the patients was 60 years, 28 (80%) had type 2 diabetes, five (14%) had type 1 diabetes and two (6%) were "new presentation" of diabetes. Forty percent were African American, 20% Caucasian, 17% mixed ethnic origin, and 14% Asian (6% Chinese and 9% Indian origin).

The scientists reported that there was there was a "striking" type 2 disease overrepresentation in those presenting with DKA (82%), suggesting acute insulinopenia in patients with COVID-19 and with type 2 diabetes, which persisted up until the time of discharge in 30% of patients previously not insulin-treated. The patients developed protracted ketonemia and ketoacidosis, with median time to ketone resolution in DKA of roughly 35 hours (range, 24 to 60 hours). In non-COVID-19 DKA cases, in contrast, the median duration of ketoacidosis was about 12 hours.

Substantial insulin resistance and possibly relative insulinopenia in severe COVID-19 was disproportionate to that seen in critical illness caused by other conditions, which might have contributed to the metabolic decompensation. The team noted that 35% of patients in the study required an increase of the fixed dose insulin infusion above the recommended insulin dose for DKA of 0.1 units/kg per hour.

In conclusion the authors reported that COVID-19 is associated with hyperglycemic emergencies in COVID-19 with overrepresentation of type 2 diabetes in patients presenting with DKA and long-lasting ketosis. The study was published on August 1, 2020 in the journal Lancet Diabetes & Endocrinology.

Related Links:
North Middlesex University Hospital


New
Gold Member
Latex Test
SLE-Latex Test
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Pan-Cancer Panel
TruSight Oncology 500
New
Host Response Immunoassay Test
MeMed BV
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.